| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8cfe4d98015afb6ce0269fe898d987a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2018-01-11^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-20^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_148899ae40b4ee04dd67b761d2f73aaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c75bfee9533335cd88220c4ceeb9f84a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23fb0d3edc814ab17eae07aa2987533b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f1398a58d6e043d94270c83ab577c00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30b12c95d0916be6549c240c347220bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30670f13b80ae42ce76448cced10d047 |
| publicationDate |
2021-04-20^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10980811-B2 |
| titleOfInvention |
Reversal of fosfomycin resistance |
| abstract |
Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2017-01-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |